| pubmed-article:12118325 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12118325 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:12118325 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:12118325 | lifeskim:mentions | umls-concept:C0007102 | lld:lifeskim |
| pubmed-article:12118325 | lifeskim:mentions | umls-concept:C0282639 | lld:lifeskim |
| pubmed-article:12118325 | lifeskim:mentions | umls-concept:C0016344 | lld:lifeskim |
| pubmed-article:12118325 | lifeskim:mentions | umls-concept:C0036043 | lld:lifeskim |
| pubmed-article:12118325 | lifeskim:mentions | umls-concept:C0520484 | lld:lifeskim |
| pubmed-article:12118325 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:12118325 | pubmed:dateCreated | 2002-7-15 | lld:pubmed |
| pubmed-article:12118325 | pubmed:abstractText | Thymidylate synthase (TS) is the molecular target of fluoropyrimidine (FP) chemotherapy, and novel anticancer drugs effective against TS-overexpressing tumors are required to treat patients with FP-refractory solid tumors. We have evaluated the inhibition of cell proliferation in vitro and antitumor activity in vivo of FdUMP[10], an oligodeoxynucleotide 10mer in which 5-fluorouracil (5-FU) is the only nucleobase. FdUMP[10] is a pro-drug of FdUMP, the TS inhibitory metabolite of FPs. FdUMP[10] was 338-fold more potent than 5-FU at inhibiting cell proliferation in the NCI 60 cell line screen. The antitumor activity of FdUMP[10] was compared to 5-FU using H-T29 xenografts in female CD-1 athymic (nu+/nu+) mice. Treatment with FdUMP[10] as a single agent (40 mg/kg/daily x 5, i.v.) delayed tumor growth and resulted in a smaller mean tumor size (T/C value = 51%, p<0.001 compared with the control group). Treatment with 5-FU (25 mg/kg/daily x 5, i.p.) had similar results as single agent FdUMP[10] (T/C value = 65%, p=0.238 compared with the FdUMP[10] treated group. Simultaneous treatment of tumor-bearing mice with both drugs (FdUMP[10] plus 5-FU) further delayed tumor growth (T/C value = 36%; p=0.003 relative to 5-FU). The results from the combined treatment group were not, however, statistically significant relative to the group receiving single agent FdUMP[10] treatment (p=0.059). Histological examination revealed systemic damage was limited to the colonic epithelium in all treatment groups and was least extensive with single agent FdUMP[10] compared to the other treatment groups. The data support the concept that FdUMP[10] is a useful prototype of a novel type of FP that is likely to be more efficacious than FPs in clinical use. | lld:pubmed |
| pubmed-article:12118325 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12118325 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12118325 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12118325 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12118325 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12118325 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12118325 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12118325 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12118325 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12118325 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12118325 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12118325 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:12118325 | pubmed:issn | 1019-6439 | lld:pubmed |
| pubmed-article:12118325 | pubmed:author | pubmed-author:GmeinerWillia... | lld:pubmed |
| pubmed-article:12118325 | pubmed:author | pubmed-author:LiuChangnianC | lld:pubmed |
| pubmed-article:12118325 | pubmed:author | pubmed-author:WillinghamMar... | lld:pubmed |
| pubmed-article:12118325 | pubmed:author | pubmed-author:LiuJinqianJ | lld:pubmed |
| pubmed-article:12118325 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12118325 | pubmed:volume | 21 | lld:pubmed |
| pubmed-article:12118325 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12118325 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12118325 | pubmed:pagination | 303-8 | lld:pubmed |
| pubmed-article:12118325 | pubmed:dateRevised | 2010-12-3 | lld:pubmed |
| pubmed-article:12118325 | pubmed:meshHeading | pubmed-meshheading:12118325... | lld:pubmed |
| pubmed-article:12118325 | pubmed:meshHeading | pubmed-meshheading:12118325... | lld:pubmed |
| pubmed-article:12118325 | pubmed:meshHeading | pubmed-meshheading:12118325... | lld:pubmed |
| pubmed-article:12118325 | pubmed:meshHeading | pubmed-meshheading:12118325... | lld:pubmed |
| pubmed-article:12118325 | pubmed:meshHeading | pubmed-meshheading:12118325... | lld:pubmed |
| pubmed-article:12118325 | pubmed:meshHeading | pubmed-meshheading:12118325... | lld:pubmed |
| pubmed-article:12118325 | pubmed:meshHeading | pubmed-meshheading:12118325... | lld:pubmed |
| pubmed-article:12118325 | pubmed:meshHeading | pubmed-meshheading:12118325... | lld:pubmed |
| pubmed-article:12118325 | pubmed:meshHeading | pubmed-meshheading:12118325... | lld:pubmed |
| pubmed-article:12118325 | pubmed:meshHeading | pubmed-meshheading:12118325... | lld:pubmed |
| pubmed-article:12118325 | pubmed:meshHeading | pubmed-meshheading:12118325... | lld:pubmed |
| pubmed-article:12118325 | pubmed:meshHeading | pubmed-meshheading:12118325... | lld:pubmed |
| pubmed-article:12118325 | pubmed:meshHeading | pubmed-meshheading:12118325... | lld:pubmed |
| pubmed-article:12118325 | pubmed:meshHeading | pubmed-meshheading:12118325... | lld:pubmed |
| pubmed-article:12118325 | pubmed:meshHeading | pubmed-meshheading:12118325... | lld:pubmed |
| pubmed-article:12118325 | pubmed:meshHeading | pubmed-meshheading:12118325... | lld:pubmed |
| pubmed-article:12118325 | pubmed:meshHeading | pubmed-meshheading:12118325... | lld:pubmed |
| pubmed-article:12118325 | pubmed:meshHeading | pubmed-meshheading:12118325... | lld:pubmed |
| pubmed-article:12118325 | pubmed:year | 2002 | lld:pubmed |
| pubmed-article:12118325 | pubmed:articleTitle | Efficacy and safety of FdUMP[10] in treatment of HT-29 human colon cancer xenografts. | lld:pubmed |
| pubmed-article:12118325 | pubmed:affiliation | Department of Biochemistry, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA. | lld:pubmed |
| pubmed-article:12118325 | pubmed:publicationType | Journal Article | lld:pubmed |
